Letter to the Editor
Expanding indications of omalizumab therapy in the absence of specific IgE
Read
3340
Timeswas read the article
996
Total PDF
2344
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 12 | 26 | 11 | 37 |
| 2025 11 | 63 | 54 | 117 |
| 2025 10 | 37 | 49 | 86 |
| 2025 9 | 49 | 13 | 62 |
| 2025 8 | 47 | 9 | 56 |
| 2025 7 | 45 | 4 | 49 |
| 2025 6 | 40 | 3 | 43 |
| 2025 5 | 22 | 4 | 26 |
| 2025 4 | 25 | 1 | 26 |
| 2025 3 | 22 | 7 | 29 |
| 2025 2 | 13 | 3 | 16 |
| 2025 1 | 14 | 4 | 18 |
| 2024 12 | 15 | 8 | 23 |
| 2024 11 | 24 | 7 | 31 |
| 2024 10 | 7 | 5 | 12 |
| 2024 9 | 17 | 7 | 24 |
| 2024 8 | 18 | 8 | 26 |
| 2024 7 | 16 | 8 | 24 |
| 2024 6 | 16 | 2 | 18 |
| 2024 5 | 16 | 6 | 22 |
| 2024 4 | 15 | 15 | 30 |
| 2024 3 | 11 | 9 | 20 |
| 2024 2 | 20 | 2 | 22 |
| 2024 1 | 24 | 15 | 39 |
| 2023 12 | 15 | 8 | 23 |
| 2023 11 | 14 | 9 | 23 |
| 2023 10 | 35 | 8 | 43 |
| 2023 9 | 19 | 15 | 34 |
| 2023 8 | 10 | 9 | 19 |
| 2023 7 | 13 | 7 | 20 |
| 2023 6 | 11 | 3 | 14 |
| 2023 5 | 5 | 4 | 9 |
| 2023 4 | 3 | 4 | 7 |
| 2023 3 | 7 | 2 | 9 |
| 2023 2 | 6 | 6 | 12 |
| 2023 1 | 8 | 5 | 13 |
| 2022 12 | 8 | 10 | 18 |
| 2022 11 | 13 | 4 | 17 |
| 2022 10 | 11 | 10 | 21 |
| 2022 9 | 9 | 7 | 16 |
| 2022 8 | 14 | 4 | 18 |
| 2022 7 | 10 | 7 | 17 |
| 2022 6 | 8 | 5 | 13 |
| 2022 5 | 8 | 6 | 14 |
| 2022 4 | 13 | 6 | 19 |
| 2022 3 | 11 | 12 | 23 |
| 2022 2 | 5 | 3 | 8 |
| 2022 1 | 11 | 4 | 15 |
| 2021 12 | 8 | 13 | 21 |
| 2021 11 | 8 | 6 | 14 |
| 2021 10 | 10 | 11 | 21 |
| 2021 9 | 9 | 20 | 29 |
| 2021 8 | 4 | 8 | 12 |
| 2021 7 | 13 | 13 | 26 |
| 2021 6 | 7 | 8 | 15 |
| 2021 5 | 11 | 9 | 20 |
| 2021 4 | 12 | 14 | 26 |
| 2021 3 | 9 | 13 | 22 |
| 2021 2 | 6 | 4 | 10 |
| 2021 1 | 5 | 3 | 8 |
| 2020 12 | 1 | 1 | 2 |
| 2020 11 | 0 | 1 | 1 |
| 2020 8 | 0 | 5 | 5 |
| 2020 7 | 0 | 2 | 2 |
| 2020 5 | 0 | 1 | 1 |
| 2020 4 | 0 | 2 | 2 |
| 2020 3 | 0 | 3 | 3 |
| 2020 2 | 0 | 5 | 5 |
| 2019 12 | 0 | 2 | 2 |
| 2019 9 | 0 | 2 | 2 |
| 2019 8 | 0 | 4 | 4 |
| 2019 7 | 0 | 9 | 9 |
| 2019 6 | 0 | 7 | 7 |
| 2019 5 | 0 | 7 | 7 |
| 2019 4 | 0 | 5 | 5 |
| 2019 3 | 0 | 3 | 3 |
| 2019 2 | 0 | 3 | 3 |
| 2019 1 | 0 | 1 | 1 |
| 2018 12 | 0 | 2 | 2 |
| 2018 11 | 0 | 6 | 6 |
| 2018 8 | 0 | 1 | 1 |
| 2018 7 | 0 | 3 | 3 |
| 2018 6 | 0 | 2 | 2 |
| 2018 2 | 6 | 0 | 6 |
| 2018 1 | 6 | 0 | 6 |
| 2017 12 | 8 | 0 | 8 |
| 2017 11 | 10 | 3 | 13 |
| 2017 10 | 12 | 2 | 14 |
| 2017 9 | 16 | 0 | 16 |
| 2017 8 | 7 | 0 | 7 |
| 2017 7 | 4 | 2 | 6 |
| 2017 6 | 12 | 15 | 27 |
| 2017 5 | 25 | 0 | 25 |
| 2017 4 | 10 | 3 | 13 |
| 2017 3 | 6 | 86 | 92 |
| 2017 2 | 10 | 7 | 17 |
| 2017 1 | 2 | 0 | 2 |
| 2016 12 | 14 | 6 | 20 |
| 2016 11 | 13 | 3 | 16 |
| 2016 10 | 17 | 13 | 30 |
| 2016 9 | 8 | 1 | 9 |
| 2016 8 | 12 | 2 | 14 |
| 2016 7 | 4 | 1 | 5 |
| 2016 6 | 10 | 7 | 17 |
| 2016 5 | 17 | 11 | 28 |
| 2016 4 | 7 | 7 | 14 |
| 2016 3 | 5 | 10 | 15 |
| 2016 2 | 10 | 13 | 23 |
| 2016 1 | 9 | 8 | 17 |
| 2015 12 | 9 | 6 | 15 |
| 2015 11 | 8 | 4 | 12 |
| 2015 10 | 13 | 8 | 21 |
| 2015 9 | 7 | 4 | 11 |
| 2015 8 | 8 | 3 | 11 |
| 2015 7 | 3 | 3 | 6 |
| 2015 6 | 3 | 2 | 5 |
| 2015 5 | 4 | 2 | 6 |
| 2015 4 | 8 | 10 | 18 |
| 2015 3 | 5 | 6 | 11 |
| 2015 2 | 7 | 1 | 8 |
| 2015 1 | 15 | 0 | 15 |
| 2014 12 | 22 | 5 | 27 |
| 2014 11 | 13 | 2 | 15 |
| 2014 10 | 22 | 7 | 29 |
| 2014 9 | 18 | 5 | 23 |
| 2014 8 | 10 | 1 | 11 |
| 2014 7 | 7 | 5 | 12 |
| 2014 6 | 5 | 0 | 5 |
| 2014 5 | 3 | 0 | 3 |
| 2014 4 | 3 | 1 | 4 |
| 2014 3 | 30 | 5 | 35 |
| 2014 2 | 26 | 8 | 34 |
| 2014 1 | 18 | 7 | 25 |
| 2013 12 | 28 | 9 | 37 |
| 2013 11 | 18 | 14 | 32 |
| 2013 10 | 20 | 5 | 25 |
| 2013 9 | 22 | 8 | 30 |
| 2013 8 | 27 | 7 | 34 |
| 2013 7 | 32 | 13 | 45 |
| 2013 6 | 11 | 1 | 12 |
| 2013 5 | 19 | 6 | 25 |
| 2013 4 | 19 | 7 | 26 |
| 2013 3 | 15 | 4 | 19 |
| 2013 2 | 5 | 5 | 10 |
| 2013 1 | 2 | 2 | 4 |
| 2012 12 | 4 | 2 | 6 |
| 2012 11 | 0 | 5 | 5 |
| 2012 10 | 2 | 2 | 4 |
| 2011 4 | 621 | 0 | 621 |
Show all
